Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...

Researchers from Tokyo Metropolitan University have found that the motion of unlabeled cells can be used to tell whether they ...

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.

The time has finally arrived, and Larian Studios has released Baldur’s Gate 3’s final major game patch. It won’t be the ...

A new study details how the North American plate is “dripping” into the mantle due to the continued influence of the Farallon Plate, which has been subducting under the continent for 200 ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

- Marks Amneal’s fourth 505(b)(2) injectable product launch in the last year BRIDGEWATER, N.J., April 01, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of ...

The following markers were found to be of interest: Clara cell 16 kDa protein (CC16), soluble Fas Ligand, cytochrome c, oxidative stress products, and CCL17 or thymus- and activation-regulated ...

as a first-line treatment for adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for stem cell transplantation. According to InvestingPro analysis, AstraZeneca ...

chemoimmunotherapy alone AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult ...